Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax RateWages, Salaries and Other
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Operating Expenses (2016 - 2026)

Amphastar Pharmaceuticals has reported Operating Expenses over the past 13 years, most recently at $58.8 million for Q4 2025.

  • For Q4 2025, Operating Expenses rose 41.65% year-over-year to $58.8 million; the TTM value through Dec 2025 reached $224.4 million, up 32.3%, while the annual FY2025 figure was $215.7 million, 28.03% up from the prior year.
  • Operating Expenses for Q4 2025 was $58.8 million at Amphastar Pharmaceuticals, down from $73.3 million in the prior quarter.
  • Over five years, Operating Expenses peaked at $73.3 million in Q3 2025 and troughed at $26.4 million in Q3 2021.
  • A 5-year average of $41.0 million and a median of $39.5 million in 2022 define the central range for Operating Expenses.
  • Biggest five-year swings in Operating Expenses: fell 19.94% in 2021 and later skyrocketed 63.34% in 2025.
  • Year by year, Operating Expenses stood at $32.0 million in 2021, then grew by 4.23% to $33.3 million in 2022, then rose by 26.47% to $42.2 million in 2023, then decreased by 1.56% to $41.5 million in 2024, then soared by 41.65% to $58.8 million in 2025.
  • Business Quant data shows Operating Expenses for AMPH at $58.8 million in Q4 2025, $73.3 million in Q3 2025, and $44.3 million in Q2 2025.